Eli Lilly will use the European Association for the Study of Diabetes 2026 meeting to detail Phase 3 retatrutide results, new Foundayo data and the first Phase 2 readout for eloraTZP, revealing how the company intends to segment an increasingly competitive obesity and diabetes market.
A new real-world study of sustained low-dose semaglutide and tirzepatide found measurable weight loss without escalation to standard maintenance doses, but researchers stress that prescription records do not prove intentional GLP-1 microdosing and the observational findings cannot establish cause and effect.
The FDA has approved Eli Lilly and Company’s Mounjaro to reduce cardiovascular death, heart attack and stroke risk in high-risk adults with type 2 diabetes, significantly broadening the clinical case for tirzepatide beyond glucose control and weight reduction.
Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.